Sign in
TerminatedPhase 1

Immunogenetic Profiling of Goeckerman Therapy in the Treatment of Psoriasis Vulgaris

Key facts

Who runs it
University of California, San Francisco
Where
San Francisco, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 1
People taking part
4 people enrolled
Started
1 Aug 2018
Ended
31 May 2024
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Goeckerman Therapy
  • Crude Coal Tar Only
  • Phototherapy Only
Record updated
3 August 2025
Why it stopped
Closing of the Goeckerman program at UCSF and loss of funding, PI left UCSF

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Male or female ≥ 18 years of age at enrollment
  • Documentation of predominately moderate to severe plaque psoriasis for at least 6 months prior to enrollment
  • Written informed consent obtained from subject and ability for subject to comply with the requirements of the study
  • Subject is considered a candidate for phototherapy or systemic therapy
  • Body Surface Area (BSA) ≥ 5%
  • Physical exam within clinically acceptable limits

Who cannot take part

  • Subject has drug-induced psoriasis
  • Evidence of abnormality of any immune cell population from a drug-induced or genetic cause
  • Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data
  • Subject with current, or a history of, severe psoriatic arthritis well controlled on current therapy
  • Patient has absolute or relative contraindication to phototherapy, including photosensitizing disorders
  • Known HIV positive status
  • Known allergy to lidocaine, other local anesthetics, or any component of local anesthetic agents
  • Subject has predominantly non-plaque form of psoriasis

Where in United States

  • UCSF Psoriasis and Skin Treatment CenterSan Francisco, United States

About the trial

What the trial wants to find out

This study examines the effect of Goeckerman therapy (a combination of phototherapy and topical crude coal tar), crude coal tar alone, and phototherapy alone on the immunologic and genetic environment within psoriatic skin lesions.

The 3 groups in the trial

  • Goeckerman TherapyExisting treatment, for comparison

    Patients with psoriasis who will receive Goeckerman therapy 5 days per week for 6 weeks.

  • Phototherapy OnlyExisting treatment, for comparison

    Patients with psoriasis who will receive narrowband ultraviolet B (NB-UVB) phototherapy 3 days per week for 12 weeks.

  • Crude Coal Tar OnlyExisting treatment, for comparison

    Patients with psoriasis who will receive skin treatment with crude coal tar only 5 days per week for 6 weeks.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
3 August 2025